Other potential treatments for tumors, particularly in the Triple WT subtype subgroup include KIT inhibitors, PARP inhibitors for ATM LoF mutations46, and in the one tumor with a ROS1 fusion, treatment with the tropomyosin receptor kinase inhibitor entrectinib35. Here, KIT is linked to neoplasm.